fluorouracil and sizofiran

fluorouracil has been researched along with sizofiran in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (40.00)	18.7374
1990's	3 (60.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asano, T; Inoue, M; Matsutani, M; Sato, S; Tsuchiya, Y; Yajima, M	1
Furue, H; Goto, Y; Kimura, T; Kondo, T; Nakao, I; Orita, K; Sato, S; Taguchi, T; Takino, T; Uchino, H	1
Abe, T; Fuse, Y; Nishida, K; Takino, T; Yokota, S; Yoshida, J	1
Fujisaki, S; Fukuma, K; Katabuchi, H; Miyazaki, K; Mizutani, H; Okamura, H	1
Arika, T; Nakahashi, S; Tsuchiya, Y; Yang, ZB	1

Trials

2 trial(s) available for fluorouracil and sizofiran

Article	Year
[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Fluorouracil; Glycosaminoglycans; Humans; Mitomycin; Mitomycins; Random Allocation; Sizofiran; Stomach Neoplasms; Tegafur	1985
Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecologic oncology, 1995, Volume: 56, Issue:3 Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; HLA-DR Antigens; Humans; Immunotherapy; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Proportional Hazards Models; Prospective Studies; Sizofiran; Survival Rate; T-Lymphocyte Subsets; Uterine Cervical Neoplasms	1995

Article

Year

[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study].

Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:6

Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Fluorouracil; Glycosaminoglycans; Humans; Mitomycin; Mitomycins; Random Allocation; Sizofiran; Stomach Neoplasms; Tegafur

1985

Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival.

Gynecologic oncology, 1995, Volume: 56, Issue:3

Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; HLA-DR Antigens; Humans; Immunotherapy; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Proportional Hazards Models; Prospective Studies; Sizofiran; Survival Rate; T-Lymphocyte Subsets; Uterine Cervical Neoplasms

1995

Other Studies

3 other study(ies) available for fluorouracil and sizofiran

Article	Year
Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cells. Cancer immunology, immunotherapy : CII, 1991, Volume: 34, Issue:1 Topics: Animals; Bone Marrow; Cell Division; Cells, Cultured; Fluorouracil; G(M1) Ganglioside; Glycosphingolipids; Killer Cells, Natural; Male; Mice; Mice, Inbred C3H; Sizofiran	1991
[Immunochemotherapy with tegafur and schizophyllan for stomach cancer--report of 2 cases]. Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:9 Topics: Aged; Drug Therapy, Combination; Female; Fluorouracil; Glycosaminoglycans; Humans; Male; Middle Aged; Sizofiran; Stomach Neoplasms; Tegafur	1983
Acceleration of natural killer (NK) cell recovery by a glucan, sizofiran, in anti-asialoGM1 antibody-treated mice. International journal of immunopharmacology, 1993, Volume: 15, Issue:7 Topics: Animals; Antigens, Surface; Bone Marrow Cells; Cytotoxicity Tests, Immunologic; Fluorouracil; G(M1) Ganglioside; Glucans; Interleukin-3; Interleukin-6; Killer Cells, Natural; Male; Mice; Mice, Inbred C3H; Mice, Inbred DBA; Rabbits; Sizofiran; Spleen; Tumor Cells, Cultured	1993